Aethlon Medical, founded in San Diego, California, focuses on developing innovative medical devices aimed at selectively removing disease-promoting particles from the circulatory system. Their core mission is to address unmet medical needs in cancer, infectious diseases, and other life-threatening conditions through novel immunotherapies. The company's flagship product, the Aethlon Hemopurifier®, is designed for the rapid depletion of cancer-promoting exosomes and circulating viruses, and has been designated as a "Breakthrough Device" by the FDA.

Notable affiliated individuals include key scientists and medical professionals who contribute to the development and clinical trials of their technologies. Aethlon Medical has garnered attention from significant investors in the healthcare sector, bolstering its research and development efforts. The company's achievements include successful clinical trials and regulatory milestones, positioning it as a pioneering force in the medical device industry. Their impact is reflected in their potential to significantly improve treatments for cancer and viral infections, enhancing patient outcomes globally.